A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens-Reference-Cited by-同舟云学术

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Published:2010-02-02 Issue:5 Volume:29 Page:1021-1028
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Bennouna Jaafar,Lang Istvan,Valladares-Ayerbes Manuel,Boer Katalin,Adenis Antoine,Escudero Pilar,Kim Tae-You,Pover Gillian M.,Morris Clive D.,Douillard Jean-Yves

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-010-9392-8.pdf

Reference19 articles.

1. Kolch W, Kotwaliwale A, Vass K, Janosch P (2002) The role of Raf kinases in malignant transformation. Expert Rev Mol Med 4:1–18

2. Wang D, Boerner SA, Winkler JD, Lorusso PM (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773:1248–1255

3. Wang JY, Wilcoxen KM, Nomoto K, Wu S (2007) Recent Advances of MEK Inhibitors and Their Clinical Progress. Curr Top Med Chem 7:1364–1378

4. Davies BR, Logie A, McKay JS et al (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209–2219

5. Yeh TC, Marsh V, Bernat BA et al (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576–1583

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. Selumetinib overcomes ITGA2-induced 5-fluorouracil resistance in colorectal cancer;International Immunopharmacology;2024-08

3. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma;Cell Death & Disease;2024-02-26

4. CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research;Cancers;2024-01-22

5. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023